Companies that seek to morph from platform to product stories have to avoid stretching themselves too thin. As they add downstream capabilities, some upstream innovation may fall by the wayside.

Last week, Curagen Corp. announced a spinout intended to side-step the problem. CRGN will place as-yet-undeveloped intellectual property focused on platform technologies into a majority-owned subsidiary called 454 Corp., allowing the parent to focus on its partnerships and product development.